Skip to content

Checked

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Phase 3
Interventional
Planned enrollment
580
Participants, all sites
U.S. sites
8
In 7 states

Study details

Conditions
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Sponsor
Regeneron Pharmaceuticals (Industry)
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Start
12/28/2023
Primary completion (expected)
04/30/2031
Last updated by sponsor
10/07/2026

Full eligibility rules, contacts and site names: NCT06149286 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • California: Los Angeles
  • Florida: Plantation
  • Indiana: Indianapolis
  • Mississippi: Hattiesburg
  • New Hampshire: Lebanon
  • New York: Stony Brook, Westbury
  • Wisconsin: Waukesha

More studies on the same topic

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/07/2026